Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prostate Cancer Approaches, Treatment Evolve In Asia Amid Wider Therapy Shifts

Executive Summary

While multiple new approaches and drugs are being developed for different stages of prostate cancer globally, many remain unavailable across Asia Pacific markets, despite a rising overall incidence of the disease. Two specialists recently shared with Scrip their views on treatment issues and optimum approaches in this fast-changing environment, and how they see the broader role of existing and new therapies developing given recent clinical results and practice.

You may also be interested in...



Clovis In Pole Position To Be First PARP For Prostate Cancer

Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.

How The Prostate Cancer Market Will Look Over Next Decade

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.

Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel